American Journal of Clinical Dermatology American Journal of Clinical Dermatology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review
ConclusionsBiologic treatments may be effective in preventing the development of psoriatic arthritis in patients with psoriasis. More research is needed given the retrospective cohort design of all studies included in the review limiting the generalizability of the results, and the conflicting results from the registry study. At present, biologic agents should not be prescribed to unselected patients with psoriasis for the sole purpose of preventing psoriatic arthritis. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 21, 2023 Category: Dermatology Source Type: research

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
ConclusionsSecukinumab was well tolerated in pediatric patients with moderate to severe and severe plaque psoriasis across age and bodyweight subgroups. The overall safety profile of secukinumab in pediatric patients was consistent with that of adult patients.ClinicalTrials.gov IdentifierNCT03668613 (Novartis Study Code CAIN457A2311, referred to as A2311), actual study start date: August 29, 2018; actual primary completion date: September 19, 2019; estimated study completion date: September 14, 2023. NCT02471144 (Novartis Study Code CAIN457A2310, referred to as A2310), study start date: September 29, 2015; primary completi...
Source: American Journal of Clinical Dermatology - June 21, 2023 Category: Dermatology Source Type: research

Climate Change, Skin Health, and Dermatologic Disease: A Guide for the Dermatologist
AbstractClimate change has a pervasive impact on health and is of clinical relevance to every organ system. Climate change-related factors impact the skin ’s capacity to maintain homeostasis, leading to a variety of cutaneous diseases. Stratospheric ozone depletion has led to increased risk of melanoma and keratinocyte carcinomas due to ultraviolet radiation exposure. Atopic dermatitis, psoriasis, pemphigus, acne vulgaris, melasma, and photoaging ar e all associated with rising levels of air pollution. Elevated temperatures due to global warming induce disruption of the skin microbiome, thereby impacting atopic dermatiti...
Source: American Journal of Clinical Dermatology - June 20, 2023 Category: Dermatology Source Type: research

Commentary on “Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology”
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 20, 2023 Category: Dermatology Source Type: research

Atopic Dermatitis Across Shades of Skin
AbstractAtopic dermatitis (AD) is a chronic, heterogeneous inflammatory skin disease that is associated with immense patient burden globally. There is increasing appreciation of disparities among patients identified as having skin of color (SOC), which often refers to patients of non-White race or non-European ancestry, but can broadly include individuals from a number of different racial, ethnic, ancestral, and skin pigmentation groups based on definition. In this narrative review, we discuss key terminology as it relates to AD across shades of skin, including modern definitions of ‘race’, ‘ethnicity’, and ‘SOC...
Source: American Journal of Clinical Dermatology - June 19, 2023 Category: Dermatology Source Type: research

Capturing the Diversity of Dermatology —What’s in a Name?
AbstractAs research related to skin of color (SOC) in dermatology continues to grow, it is increasingly important to precisely define terminology. The terms ‘SOC’, ‘race’, and ‘ethnicity’ are frequently used to analyze differences in dermatologic disease onset, severity, and outcomes. These terms are used interchangeably, are ill-defined across research studies, and frequently conflate biologic and socially constructed categories. SOC has be en thought to represent differing degrees of pigment or melanin in the skin, however skin pigment is quite variable among races and ethnicities. Furthermore, certain indivi...
Source: American Journal of Clinical Dermatology - June 16, 2023 Category: Dermatology Source Type: research

Targeting Inflammation in Acne: Current Treatments and Future Prospects
This article will provide an overview of emerging treatments of acne and their link to our current and improved understanding of acne pathogenesis. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 16, 2023 Category: Dermatology Source Type: research

Baricitinib: A Review in Severe Alopecia Areata
AbstractBaricitinib (Olumiant®), a Janus kinase (JAK) inhibitor, is the first drug approved for the treatment of severe alopecia areata in the USA and the EU. Severe alopecia areata is usually difficult to treat and relapse is common. Patients with this disorder are more likely to suffer from anxiety and depression. In two pivotal placebo-controlled phase 3 clinical trials in adults with severe alopecia areata, oral baricitinib once daily was associated with clinically meaningful scalp, eyebrow, and eyelash hair regrowth over 36 weeks. Baricitinib was generally well tolerated with the most common adverse events being infe...
Source: American Journal of Clinical Dermatology - June 16, 2023 Category: Dermatology Source Type: research

Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis  in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
ConclusionThis study provides strong evidence of a sustained response obtained by upadacitinib in AD patients, who had failed to respond to conventional or biological systemic agents, through 48 weeks of observation. Upadacitinib was  also demonstrated to be advantageous in terms of flexibility in dose reduction or escalation as upadacitinib dose was shaped on clinical needs that, in a real-world setting, might frequently change. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 15, 2023 Category: Dermatology Source Type: research

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Beh çet’s Syndrome
ConclusionsThe incidence of serious TEAEs and TEAEs of special interest was low despite long-term exposure, further establishing apremilast as a safe oral option for long-term use across indications with a favorable benefit –risk profile.Clinical Trial RegistrationNCT00773734, NCT01194219, NCT01232283, NCT01690299, NCT01988103, NCT02425826, NCT03123471, NCT03721172, NCT01172938, NCT01212757, NCT01212770, NCT01307423, NCT01925768, NCT00866359, NCT02307513.Graphical Abstract (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 14, 2023 Category: Dermatology Source Type: research

Dupilumab Provides Clinically Meaningful Responses in Children Aged 6 –11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
ConclusionTreatment with dupilumab provides significant and sustained improvements within 2 weeks in AD signs, symptoms, and QoL in almost all children with severe AD, including those who did not achieve clear or almost clear skin by week 16.Trial RegistrationNCT03345914.Video Abstract: Does dupilumab provide clinically meaningful responses in children 6 to 11 years old with severe atopic dermatitis? (MP4 99484 kb) (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 10, 2023 Category: Dermatology Source Type: research

Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries
ConclusionsAlthough mortality rates and trends were found to decrease, global incidence has increased, especially in older age groups and males. Whilst incidence increase may be attributed to improved healthcare infrastructure and cancer detection methods, the growing prevalence of lifestyle and metabolic risk factors in developed countries should not be discounted. Future research should explore underlying variables behind epidemiological trends. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 10, 2023 Category: Dermatology Source Type: research

Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study
Conclusions and RelevanceOur study found no evidence to support an association between TCI use and the risks of almost all cancers compared with TCS use in patients with AD, but physicians should be aware of potentially higher risks of leukemia with TCI use. This study represents the first population-based study focused on the cancer risk of TCI use among patients with AD in an Asian population. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 6, 2023 Category: Dermatology Source Type: research

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
This article reviews the current evidence about lebrikizumab in the management of AD. The phase II and phase III trials seem to corroborate efficacy of lebrikizumab in the treatment of moderate-to-severe AD, as shown by significant improvement of Eczema Area and Severity Index, body surface area, and pruritus scores. Also, lebrikizumab demonstrated favorable safety and tolerability profiles, with the majority of patients experiencing no significant adverse events. Lebrikizumab seems to be a promising emerging targeted biological agent for patients with moderate-to-severe AD. More data on the long-term efficacy and safety, ...
Source: American Journal of Clinical Dermatology - June 2, 2023 Category: Dermatology Source Type: research

Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
ConclusionsApremilast treatment demonstrated greater improvements in disease severity and patient-reported symptoms versus placebo at week 16 in Japanese patients with PPP with sustained improvements through week 32. No new safety signals were observed.ClinicalTrials.govNCT04057937. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 26, 2023 Category: Dermatology Source Type: research